Status:

RECRUITING

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Lead Sponsor:

Ono Pharmaceutical Co. Ltd

Conditions:

Colorectal Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® when added to mFOLFOX6 and bevacizumab versus SOC as first-line treatment for advanced CRC.

Detailed Description

Potential participants will be consented and screened for study eligibility. Eligible participants will be randomized in a 1:1:1 ratio to one of the three study intervention arms. Study intervention w...

Eligibility Criteria

Inclusion

  • Histologically confirmed advanced (locally advanced or metastatic) colorectal cancer not amenable to curative resection
  • ECOG Performance Status of 0-1
  • No prior systemic treatment for advanced local or mCRC
  • Participants whose tumor is positive for PD-L1 expression as determined at a central laboratory

Exclusion

  • Participants with high microsatellite instability (MSI-High), or mismatch repair deficient (dMMR) tumor
  • Participants with BRAF V600E mutation
  • Unable to swallow tablets.
  • Participants with complication or history of interstitial lung disease, pneumonitis or pulmonary fibrosis
  • Participants with an active, known or suspected autoimmune disease.
  • Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
  • Other protocol-defined inclusion/exclusion criteria apply

Key Trial Info

Start Date :

November 18 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2028

Estimated Enrollment :

144 Patients enrolled

Trial Details

Trial ID

NCT06948448

Start Date

November 18 2025

End Date

October 1 2028

Last Update

December 15 2025

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

Mayo Clinic Arizona

Phoenix, Arizona, United States, 85054

2

USC Norris Comprehensive Cancer Center

Los Angeles, California, United States, 90033

3

Mayo Clinic Florida

Jacksonville, Florida, United States, 32224

4

The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States, 43221